Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer.
Linda Holmstrand ZetterlundFuat CelebiogluRimma AxelssonJana de BonifaceJan FrisellPublished in: Breast cancer research and treatment (2017)
In clinically node-negative patients, SLNB before NAST is highly reliable. With this sequence, ALND and regional radiotherapy can be safely omitted in patients with a negative SLNB provided good clinical response to NAST. Additionally, SLNB-positive patients upfront will receive correct nodal staging unaffected by NAST and be consequently offered adjuvant locoregional treatment according to current guidelines pending the results of ongoing randomized trials.
Keyphrases
- lymph node
- end stage renal disease
- early stage
- sentinel lymph node
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- clinical trial
- radiation therapy
- neoadjuvant chemotherapy
- randomized controlled trial
- squamous cell carcinoma
- rectal cancer
- patient reported outcomes
- bone marrow
- clinical practice
- radiation induced
- mesenchymal stem cells
- ultrasound guided
- replacement therapy
- patient reported
- phase iii